Skip to content
Save up to 80% on your medications — Fast delivery
Singulair
Guaranteed quality
Discreet shipping
Returns

Singulair - Montelukast

4 customer reviews
Delivery: 4–7 days
Secure payment methods
24/7 Support
Active ingredient: Montelukast
Package Per unit Price
SSL Secure
Certified pharmacy
Money-back guarantee

Singulair is an oral medicine containing montelukast, a leukotriene receptor antagonist. It is for adults and children with asthma prevention needs or allergic rhinitis symptoms. It helps by blocking leukotrienes that drive airway tightening and allergy inflammation.

What is it?

Singulair is a medication containing montelukast used for long-term control of asthma and for symptom relief in allergic rhinitis. It is used in adults and children as part of a prevention plan, not as a quick fix for sudden breathing attacks. Singulair works by blocking leukotrienes, immune chemicals that tighten airways and drive allergy inflammation.

Composition

Active ingredient: montelukast (often as montelukast sodium). Tablets contain montelukast in a defined strength (commonly 10 mg per tablet for adults). Excipients vary by manufacturer and may include fillers, binders, and film-coating agents that form the tablet and help stability.

How to use?

Used for long-term control of asthma symptoms and for prevention of exercise-induced bronchoconstriction in eligible patients. Also used to relieve symptoms of seasonal or perennial allergic rhinitis such as sneezing, runny nose, and nasal congestion. It is taken by mouth as tablets according to age and indication.

How does it work?

  • Route: oral (tablet).
  • Dose (as montelukast): adults and adolescents ≥15 years: 10 mg.
  • Frequency: 1 time/day.
  • Timing: take in the evening; may be taken with or without food.
  • Duration: long-term daily use for asthma/allergic rhinitis as prescribed; reassess control periodically.
  • Exercise-induced bronchoconstriction (≥15 years): 10 mg once, taken at least 2 hours before exercise; do not take more than 10 mg in 24 hours.

Indications

Singulair is a medication containing montelukast used for long-term control of asthma and for symptom relief in allergic rhinitis. It is used in adults and children as part of a prevention plan, not as a quick fix for sudden breathing attacks.

Singulair (montelukast) is taken to reduce day-to-day asthma symptoms and lower the chance of flare-ups, and it is also used for seasonal and year-round allergic rhinitis. Asthma is a chronic inflammatory condition of the airways, where triggers (viral infections, dust, smoke, exercise) can cause tightness, wheeze, cough, and breathlessness. Because montelukast is taken by mouth as a pill, clinicians often use it when patients struggle with inhaler technique or need extra control on top of inhaled therapy.

If your asthma symptoms wake you at night or you are using a reliever inhaler more often than usual, that pattern usually signals poor control—Singulair may be used as part of a step-up plan, but it should not be relied on as the only controller.

Comparison

Singulair is best thought of as a controller that targets leukotriene-driven inflammation. Many asthma plans still centre on inhaled steroids because they directly reduce airway inflammation where it occurs, and short-acting bronchodilators are used for rapid relief of sudden symptoms. For allergic rhinitis, some people do well on oral antihistamines alone, while others need an intranasal steroid for congestion.

Quick comparison by role

Option Main role What to expect
Singulair (montelukast) Daily prevention for asthma and allergic rhinitis; selected use for exercise-induced bronchospasm Gradual benefit; oral pill; neuropsychiatric warning in a small minority
Inhaled steroids (e.g., Pulmicort) First-line controller for many asthma severities Strong anti-inflammatory effect in airways; needs correct inhaler technique
Combination inhalers (e.g., Symbicort) Controller (and in some plans, reliever) for moderate–severe asthma Addresses inflammation and bronchospasm together; dosing depends on the asthma plan

For allergies, oral antihistamines such as Claritin or Zyrtec mainly target histamine-driven sneezing and itch, while Singulair targets leukotriene pathways, which can matter more when congestion and asthma overlap. If your dominant problem is sudden wheeze, a short-acting bronchodilator remains the rapid option; Singulair is built for prevention.

Contraindications

  • Hypersensitivity to montelukast or tablet components
  • Phenylketonuria (PKU) for chewable formulations that may contain aspartame (source of phenylalanine)
  • Use for immediate relief of an acute asthma attack (not a fast-acting bronchodilator)

Not recommended for

Singulair is not for you if any of the following apply:

  • Allergy or hypersensitivity to montelukast or tablet components.
  • Phenylketonuria (PKU): chewable montelukast formulations may contain aspartame (a source of phenylalanine), so PKU needs explicit clinician guidance.
  • You need immediate relief for an acute asthma attack: Singulair is not a fast-acting bronchodilator.

Extra caution is used when there is a history of depression, anxiety, or other mental health conditions, because neuropsychiatric effects can be harder to detect early in that setting.

Side effects

Most people tolerate Singulair well, and the common side effects seen in practice are usually mild: headache, stomach pain, diarrhoea, and upper respiratory infection symptoms. Parents also report ear pain and runny nose in some children, which can be hard to separate from the viral infections that also trigger asthma symptoms. If you notice stomach upset, taking the dose at the same time each day and keeping evening meals consistent can help you spot whether food timing affects you.

The side effects that deserve real attention are the neuropsychiatric ones. The U.S. FDA requires a stronger warning about the risk of neuropsychiatric events associated with Singulair and generic montelukast, including mood changes, agitation, anxiety, depression, sleep disturbance, and suicidal thoughts in rare cases [4]. These reactions can start days after initiation or after weeks of use, and they can also appear after dose changes. In pharmacy practice, the “tell” is often a sudden change from normal sleep to vivid nightmares or new irritability that family members notice before the patient connects it to medication.

Seek urgent medical care for signs of a serious allergic reaction such as swelling of the face, lips, tongue, or throat with breathing difficulty. Stop-and-watch decisions should be clinician-led for asthma control, because stopping a controller can destabilise symptoms quickly in some patients.

A small but useful tracking trick: for the first 2–3 weeks, jot down sleep quality and mood in a simple notes app—if anything shifts, you have a clear timeline to share with your clinician.

Common mistakes

Small errors can make Singulair look like it failed.

  • Using Singulair as a rescue medicine: it will not open the airways quickly during acute bronchospasm.
  • Taking it only when symptomatic: asthma and allergic rhinitis control improves with regular use, not “as needed” dosing.
  • Wrong timing for exercise: dosing right before sport instead of at least 2 hours before.
  • Doubling up after a missed dose: this raises side-effect risk without improving control.
  • Stopping inhaled steroids abruptly: symptom relief can mask underlying inflammation, then flare-ups rebound.

One more niche issue I’ve seen: patients starting Singulair during a stressful period and assuming new sleep problems are “life,” not medication. Connecting timing matters.

Frequently asked questions

No—Singulair is a controller medicine for prevention, not a rescue bronchodilator for sudden symptoms. For acute bronchospasm, asthma action plans typically rely on rapid relievers, while controller medicines reduce attack frequency over time. This distinction matches the controller/reliever model used in WHO asthma resources updated through 2026 .

Some people notice less night cough or less exercise tightness within days, while others need a few weeks of consistent dosing to judge benefit. The response also depends on whether leukotrienes are a main driver of your symptoms, which is common when allergic rhinitis and asthma overlap. EMA documentation frames montelukast as a preventive therapy where response is assessed over time, not dose-by-dose .

Treat new anxiety, depression, agitation, nightmares, or suicidal thoughts as a safety signal, not as something to push through. The FDA strengthened warnings about neuropsychiatric events with Singulair and montelukast, and clinicians usually want to hear about symptoms early so they can adjust treatment safely . Keep a simple timeline of when symptoms started and whether any other medicine changes occurred.

Yes, Singulair is used for seasonal allergic rhinitis and year-round allergic rhinitis in selected patients, including those who cannot tolerate or do not respond well to other options. It tends to make most sense when nasal symptoms and chest symptoms travel together, or when congestion is linked to leukotriene activity. MOHAP clinical education for respiratory care supports tailoring therapy to symptom pattern rather than a one-size approach .

Paediatric use is common, with age-based dosing using lower strengths such as 4 mg and 5 mg. The child’s asthma plan should also spell out reliever use and trigger management, since montelukast is preventive and does not replace rapid relief. WHO guidance for childhood asthma stresses regular review because control level can change across school terms and viral seasons .

The most clinically relevant interactions are with strong enzyme inducers that can reduce montelukast levels, such as phenobarbital and rifampicin. When these are started or stopped, asthma control should be reassessed because the montelukast effect can shift. EMA interaction notes for montelukast support this mechanism-based caution with enzyme inducers .

Front view Front view
Side view Side view
Back view Back view

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.

Singulair — Comparison with alternatives

Duration of Singulair Treatment

Singulair is commonly used for long-term management, with duration tied to symptom control, seasonality of allergies, and asthma severity. For mild asthma, some patients use montelukast during high-trigger periods and then step down after a stable period, while others remain on a daily controller for longer. Prolonged Singulair use is not unusual, yet the benefit should be reviewed periodically: if you have been stable for months, clinicians often reassess triggers, lung function trends, and whether the current step is still needed.

If Singulair is stopped, asthma symptoms can return in days to weeks in susceptible patients. Planning a step-down with clear reliever instructions is safer than stopping abruptly during an active allergy season.

Reviews and Experiences

H
Hassan, 34
Dubai
10 weeks
Verified
My cough at night eased after about two weeks, and I stopped waking up wheezing. I still kept my inhaler plan the same. Headache happened the first few days, then faded.
14/02/2026
M
Mariam, 29
Abu Dhabi
3 weeks
Verified
Breathing felt steadier during workouts, but my sleep got strange with vivid dreams in week one. I flagged it early and we switched my plan. The breathing benefit was real, but the sleep issue wasn’t for me.
03/11/2025
O
Omar, 41
Sharjah
4 months
Verified
Allergy season usually blocks my nose and triggers tight chest. This time the congestion and wheeze were both calmer. I missed doses on weekends at first and didn’t notice much; once I took it daily, it made a difference.
26/01/2026
S
Sara, 37
Al Ain
6 weeks
Verified
My son’s night cough reduced and he needed his reliever less. We did notice crankiness for a few days, which settled, but I watched it closely because I’d read about mood effects.
08/03/2026

Sources

  1. MOHAP (Ministry of Health and Prevention) (2026). Asthma: Patient Education and Controller Treatment Principles.
  2. European Medicines Agency (EMA) (2026). Montelukast: Summary of Product Characteristics and Clinical Pharmacology Overview.
  3. World Health Organization (WHO) (2026). Asthma: Key Facts and Evidence-Based Management Resources.
  4. U.S. Food and Drug Administration (FDA) (2026). Boxed Warning: Neuropsychiatric Events for Singulair (montelukast) and Generic Montelukast.
  5. U.S. Food and Drug Administration (FDA) (2025). FDA Approvals: Generic Montelukast for Asthma and Allergic Rhinitis.
Get our free app Shop faster and track your orders 3.8 · 1,437 reviews Install